SCHEMBL4629627

SCHEMBL4629627

O=C(NC(=O)C1CCNC1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.50
CYP1A2 P05177 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
ATM Q13315 1/20 0.43
ALDH1A1 P00352 1/20 0.41
P2RY14 Q15391 1/20 0.41
JAK3 P52333 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR2C P28335 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL407286 0.78 KMT2A (0.53) KMT2A
SCHEMBL27947005 0.78 KMT2A (0.43) JAK3KMT2A
SCHEMBL14505992 0.78 HPGD (0.60) NPC1RAB9AJAK3KMT2A
SCHEMBL1318504 0.78 HPGD (0.60) NPC1RAB9AJAK3KMT2A
SCHEMBL6371533 0.77 HDAC1 (0.50) NPC1ALDH1A1KMT2A
SCHEMBL4266412 0.77 KCNK3 (0.61) CYP1A2NPC1RAB9AKCNK3KCNK9
Hydrochloric Acid SCHEMBL440964 0.77 KMT2A (0.56) KMT2A
SCHEMBL29060808 0.77 HPGD (0.56) NPC1RAB9AKMT2AHTR2C
SCHEMBL3879671 0.77 NPC1 (0.47) NPC1RAB9AATMKMT2A
SCHEMBL29060806 0.77 HPGD (0.56) NPC1RAB9AKMT2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606247-A Imide compound and preparation method and application thereof 温州医科大学 2023-08-18 CN disclosed
EP-1919907-A2 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-14 EP disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed